M&A seminar: EU legal & regulatory aspects

Some time ago I wrote about issues often overlooked in medical devices M&A transactions. Because of the reactions to it I decided to organise a seminar at my law firm’s Amsterdam office about it on Wednesday 13 April that should provide a good insights in the subject. With speakers from notified body BSi (Jan van Lochum, vice president Healthcare), from DRS regulatory consultants (Hans van Dulmen) and of course myself you will get a good insight in the regulatory and legal aspects of mergers and acquisitions in the medical devices company. The seminar is free and will be made available in real time as webinar, so if you cannot travel you can participate if you have a computer with internet connection and a telephone. Participation is free. I hope to welcome many of my readers!

Here is the invitation, just for good measure (you may need to click the CT screen to start the animation and see the invite):

Information and Registration

Wednesday, April 13, 2011

Greenberg Traurig, LLP
Atrium Building, 8th floor
Strawinskylaan 3127
1077 ZX Amsterdam

Registration and coffee: 15.30
Seminar starts: 16.00
Drinks and snacks: 18.30

This seminar will provide a unique opportunity to hear about mergers and acquisitions (M&A) in the medical device industry from a notified body, from a regulatory consultant and from the legal viewpoint, ensuring high quality yet practical content and ample opportunity to get your questions answered.

To register for this seminar, please send an email to medtech@eu.gtlaw.com with your name, the names of any colleagues you would like to register, and your contact information.

To register for the webinar, please click here.

Whether you will attend in person or online, your response is requested no later than Wednesday, April 6.

If you have any questions about this seminar, please contact Wycke van der Ploeg  at vanderploegw@eu.gtlaw.com or +31 (0) 20 30 17 400.

Navigate through our knowledgebase

Related articles


New sort of applicable economic operators regulation: the Market Surveillance Regulation

Attentive attendees of my presentations will have remarked in my presentations about economic operators that essential parts of the general Goods Package were being amended and that this may affect companies in…

Read more


Transparency vs. Confidentiality: EFSA’s new role as from March 2021

Last month, the European Council formally adopted the new Regulation on the transparency of the EU risk assessment in the food chain, which will be applicable as of 26 March 2021. As is in the name, the new provisions aim at increased transparency of EU risk assessment, which for a large deal means strengthening the […]


€ 500 per data subject – a quantification of why GDPR matters

Clients often ask me why they should invest in General Data Protection Regulation (GDPR) compliance so much. For medical devices and medicines regulatory compliance, they get it to an extent. Non-compliant devices…

Read more